{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:13:35Z","timestamp":1789377215555,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mutations of the gene encoding the major component of Lewy bodies (LB), \u03b1-synuclein (\u03b1-syn), cause autosomal dominant forms of Parkinson\u2019s disease (PD), whereas loss-of-function mutations of the gene encoding the multifunctional E3 ubiquitin-protein ligase Parkin account for autosomal recessive forms of the disease. Parkin overproduction protects against \u03b1-syn-dependent neurodegeneration in various <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> models, but it remains unclear whether this process is affected by Parkin deficiency. We addressed this issue, by carrying out more detailed analyses of transgenic mice overproducing the A30P variant of human \u03b1-syn (hA30P\u03b1-syn) and with two, one or no <jats:italic>parkin<\/jats:italic> knockout alleles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Longitudinal behavioral follow-up of these mice indicated that Parkin depletion delayed disease-predictive sensorimotor impairment due to \u03b1-syn accumulation, in a dose-dependent fashion. At the end stage of the disease, neuronal deposits containing fibrillar \u03b1-syn species phosphorylated at S129 (P<jats:sup>S129<\/jats:sup>\u03b1-syn) were the predominant neuropathological feature in hA30P\u03b1-syn mice, regardless of their <jats:italic>parkin<\/jats:italic> expression. Some of these deposits colocalized with the LB markers ubiquitin and \u03b1-syn truncated at D135 (\u03b1-synD135), indicating that P<jats:sup>S129<\/jats:sup>\u03b1-syn is subjected to secondary posttranslational modification (PTM); these features were not significantly affected by <jats:italic>parkin<\/jats:italic> dysfunction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest that Parkin deficiency acts as a protective modifier in \u03b1-syn-dependent neurodegeneration, without overtly affecting the composition and characteristics of \u03b1-syn deposits in end-stage disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2202-14-135","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T16:39:31Z","timestamp":1383669571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in \u03b1-synuclein transgenic mice"],"prefix":"10.1186","volume":"14","author":[{"given":"Margot","family":"Fournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Garrigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Muriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal A","family":"Lashuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Tezenas","family":"du Montcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"3433_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","volume":"183","author":"A Oueslati","year":"2010","unstructured":"Oueslati A, Fournier M, Lashuel HA: Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res. 2010, 183: 115-145.","journal-title":"Prog Brain Res"},{"issue":"40","key":"3433_CR2","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006, 281 (40): 29739-29752. 10.1074\/jbc.M600933200.","journal-title":"J Biol Chem"},{"issue":"2","key":"3433_CR3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T: Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4 (2): 160-164.","journal-title":"Nat Cell Biol"},{"issue":"45","key":"3433_CR4","doi-asserted-by":"publisher","first-page":"44405","DOI":"10.1074\/jbc.M308041200","volume":"278","author":"GK Tofaris","year":"2003","unstructured":"Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003, 278 (45): 44405-44411. 10.1074\/jbc.M308041200.","journal-title":"J Biol Chem"},{"issue":"50","key":"3433_CR5","doi-asserted-by":"publisher","first-page":"49071","DOI":"10.1074\/jbc.M208046200","volume":"277","author":"M Hasegawa","year":"2002","unstructured":"Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002, 277 (50): 49071-49076. 10.1074\/jbc.M208046200.","journal-title":"J Biol Chem"},{"issue":"1","key":"3433_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9440(10)63633-4","volume":"163","author":"DM Sampathu","year":"2003","unstructured":"Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM: Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol. 2003, 163 (1): 91-100. 10.1016\/S0002-9440(10)63633-4.","journal-title":"Am J Pathol"},{"issue":"6","key":"3433_CR7","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1074\/jbc.M704809200","volume":"283","author":"R Rott","year":"2008","unstructured":"Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S: Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem. 2008, 283 (6): 3316-3328.","journal-title":"J Biol Chem"},{"issue":"1","key":"3433_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/bi0485528","volume":"44","author":"T Nonaka","year":"2005","unstructured":"Nonaka T, Iwatsubo T, Hasegawa M: Ubiquitination of alpha-synuclein. Biochemistry. 2005, 44 (1): 361-368. 10.1021\/bi0485528.","journal-title":"Biochemistry"},{"issue":"4","key":"3433_CR9","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T: Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998, 152 (4): 879-884.","journal-title":"Am J Pathol"},{"issue":"1","key":"3433_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1471-4159.2001.00021.x","volume":"76","author":"BC Campbell","year":"2001","unstructured":"Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX: The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem. 2001, 76 (1): 87-96.","journal-title":"J Neurochem"},{"issue":"6","key":"3433_CR11","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","volume":"102","author":"W Li","year":"2005","unstructured":"Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, et al: Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A. 2005, 102 (6): 2162-2167. 10.1073\/pnas.0406976102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"3433_CR12","doi-asserted-by":"publisher","first-page":"22670","DOI":"10.1074\/jbc.M501508200","volume":"280","author":"CW Liu","year":"2005","unstructured":"Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ: A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem. 2005, 280 (24): 22670-22678. 10.1074\/jbc.M501508200.","journal-title":"J Biol Chem"},{"issue":"11","key":"3433_CR13","first-page":"3257","volume":"119","author":"L Chen","year":"2009","unstructured":"Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB: Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest. 2009, 119 (11): 3257-3265.","journal-title":"J Clin Invest"},{"issue":"10","key":"3433_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm1001-1144","volume":"7","author":"KK Chung","year":"2001","unstructured":"Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001, 7 (10): 1144-1150. 10.1038\/nm1001-1144.","journal-title":"Nat Med"},{"issue":"Pt 3","key":"3433_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/brain\/awl382","volume":"130","author":"A Eslamboli","year":"2007","unstructured":"Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D: Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007, 130 (Pt 3): 799-815.","journal-title":"Brain"},{"issue":"8","key":"3433_CR16","doi-asserted-by":"publisher","first-page":"e6629","DOI":"10.1371\/journal.pone.0006629","volume":"4","author":"M Fournier","year":"2009","unstructured":"Fournier M, Vitte J, Garrigue J, Langui D, Dullin J-P, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, et al: Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One. 2009, 4 (8): e6629-10.1371\/journal.pone.0006629.","journal-title":"PLoS One"},{"issue":"4","key":"3433_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002, 34 (4): 521-533. 10.1016\/S0896-6273(02)00682-7.","journal-title":"Neuron"},{"issue":"13","key":"3433_CR18","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL: Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -\u2009>\u2009Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002, 99 (13): 8968-8973. 10.1073\/pnas.132197599.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"3433_CR19","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.1073\/pnas.152339799","volume":"99","author":"C Lo Bianco","year":"2002","unstructured":"Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P: Alpha - synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A. 2002, 99 (16): 10813-10818. 10.1073\/pnas.152339799.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5456","key":"3433_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287 (5456): 1265-1269. 10.1126\/science.287.5456.1265.","journal-title":"Science"},{"issue":"10","key":"3433_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI200215777","volume":"110","author":"M Neumann","year":"2002","unstructured":"Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al: Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002, 110 (10): 1429-1439.","journal-title":"J Clin Invest"},{"issue":"46","key":"3433_CR22","doi-asserted-by":"publisher","first-page":"16884","DOI":"10.1523\/JNEUROSCI.3967-11.2011","volume":"31","author":"H Sato","year":"2011","unstructured":"Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T: Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci. 2011, 31 (46): 16884-16894. 10.1523\/JNEUROSCI.3967-11.2011.","journal-title":"J Neurosci"},{"issue":"16","key":"3433_CR23","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","volume":"20","author":"H van der Putten","year":"2000","unstructured":"van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, et al: Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000, 20 (16): 6021-6029.","journal-title":"J Neurosci"},{"issue":"2","key":"3433_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1471-4159.2004.02728.x","volume":"91","author":"M Yamada","year":"2004","unstructured":"Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004, 91 (2): 451-461. 10.1111\/j.1471-4159.2004.02728.x.","journal-title":"J Neurochem"},{"issue":"4","key":"3433_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","volume":"91","author":"O Corti","year":"2011","unstructured":"Corti O, Lesage S, Brice A: What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011, 91 (4): 1161-1218. 10.1152\/physrev.00022.2010.","journal-title":"Physiol Rev"},{"issue":"21","key":"3433_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"CB Lucking","year":"2000","unstructured":"Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al: Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000, 342 (21): 1560-1567. 10.1056\/NEJM200005253422103.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3433_CR27","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1002\/mds.22798","volume":"25","author":"TM Dawson","year":"2010","unstructured":"Dawson TM, Dawson VL: The role of parkin in familial and sporadic Parkinson's disease. Mov Disord. 2010, 25 (Suppl 1): S32-39.","journal-title":"Mov Disord"},{"key":"3433_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2202-5-14","volume":"5","author":"AF Haywood","year":"2004","unstructured":"Haywood AF, Staveley BE: Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 2004, 5: 14-10.1186\/1471-2202-5-14.","journal-title":"BMC Neurosci"},{"issue":"6","key":"3433_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0896-6273(02)01125-X","volume":"36","author":"L Petrucelli","year":"2002","unstructured":"Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, et al: Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002, 36 (6): 1007-1019. 10.1016\/S0896-6273(02)01125-X.","journal-title":"Neuron"},{"issue":"6","key":"3433_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0896-6273(03)00143-0","volume":"37","author":"Y Yang","year":"2003","unstructured":"Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B: Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 2003, 37 (6): 911-924. 10.1016\/S0896-6273(03)00143-0.","journal-title":"Neuron"},{"issue":"14","key":"3433_CR31","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1523\/JNEUROSCI.0414-06.2006","volume":"26","author":"R von Coelln","year":"2006","unstructured":"von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, et al: Inclusion body formation and neurodegeneration are parkin-independent in a mouse model of alpha-synucleinopathy. J Neurosci. 2006, 26 (14): 3685-3696. 10.1523\/JNEUROSCI.0414-06.2006.","journal-title":"J Neurosci"},{"issue":"6","key":"3433_CR32","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0002-9440(10)63072-6","volume":"159","author":"PJ Kahle","year":"2001","unstructured":"Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, et al: Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol. 2001, 159 (6): 2215-2225. 10.1016\/S0002-9440(10)63072-6.","journal-title":"Am J Pathol"},{"issue":"18","key":"3433_CR33","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/hmg\/ddg239","volume":"12","author":"JM Itier","year":"2003","unstructured":"Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, et al: Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet. 2003, 12 (18): 2277-2291. 10.1093\/hmg\/ddg239.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"3433_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/NEN.0b013e3181efc01c","volume":"69","author":"J Vitte","year":"2010","unstructured":"Vitte J, Traver S, Maues De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A: Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol. 2010, 69 (9): 959-972. 10.1097\/NEN.0b013e3181efc01c.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"3433_CR35","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00702-007-0775-8","volume":"114","author":"C Jan","year":"2007","unstructured":"Jan C, Muriel MP, Rolland AS, Hirsch EC, Francois C: Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat. J Neural Transm. 2007, 114 (12): 1509-1517. 10.1007\/s00702-007-0775-8.","journal-title":"J Neural Transm"},{"key":"3433_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-60327-834-8_5","volume":"527","author":"TE Thingholm","year":"2009","unstructured":"Thingholm TE, Larsen MR: The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. Methods Mol Biol. 2009, 527: 57-66. 10.1007\/978-1-60327-834-8_5. xi","journal-title":"Methods Mol Biol"},{"issue":"4","key":"3433_CR37","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1074\/jbc.M109.081950","volume":"285","author":"MK Mbefo","year":"2010","unstructured":"Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, et al: Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem. 2010, 285 (4): 2807-2822. 10.1074\/jbc.M109.081950.","journal-title":"J Biol Chem"},{"issue":"24","key":"3433_CR38","doi-asserted-by":"publisher","first-page":"16895","DOI":"10.1074\/jbc.M800747200","volume":"283","author":"KE Paleologou","year":"2008","unstructured":"Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, et al: Phosphorylation at Ser-129 but not the phosphomimics S129E\/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008, 283 (24): 16895-16905. 10.1074\/jbc.M800747200.","journal-title":"J Biol Chem"},{"issue":"5","key":"3433_CR39","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1074\/jbc.C800206200","volume":"284","author":"KJ Inglis","year":"2009","unstructured":"Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, et al: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009, 284 (5): 2598-2602.","journal-title":"J Biol Chem"},{"issue":"24","key":"3433_CR40","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1523\/JNEUROSCI.21-24-09549.2001","volume":"21","author":"L Stefanis","year":"2001","unstructured":"Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001, 21 (24): 9549-9560.","journal-title":"J Neurosci"},{"issue":"9","key":"3433_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/hmg\/10.9.919","volume":"10","author":"Y Tanaka","year":"2001","unstructured":"Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, LD V, Dawson TM, Ross CA: Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001, 10 (9): 919-926. 10.1093\/hmg\/10.9.919.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3433_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10863-009-9258-y","volume":"42","author":"KA Lewis","year":"2010","unstructured":"Lewis KA, Yaeger A, DeMartino GN, Thomas PJ: Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr. 2010, 42 (1): 85-95. 10.1007\/s10863-009-9258-y.","journal-title":"J Bioenerg Biomembr"},{"issue":"12","key":"3433_CR43","doi-asserted-by":"publisher","first-page":"10814","DOI":"10.1074\/jbc.M110.132514","volume":"286","author":"V Choubey","year":"2011","unstructured":"Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A: Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011, 286 (12): 10814-10824. 10.1074\/jbc.M110.132514.","journal-title":"J Biol Chem"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-14-135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:07:11Z","timestamp":1630548431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-14-135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3433"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-14-135","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]},"assertion":[{"value":"27 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"135"}}